162 related articles for article (PubMed ID: 12214871)
1. Which dosing scheme is suitable for the taxanes? An in vitro model.
Sanli UA; Uslu R; Karabulut B; Sezgin C; Saydam G; Omay SB; Goker E
Arch Pharm Res; 2002 Aug; 25(4):550-5. PubMed ID: 12214871
[TBL] [Abstract][Full Text] [Related]
2. Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells.
Witters LM; Santala SM; Engle L; Chinchilli V; Lipton A
Am J Clin Oncol; 2003 Feb; 26(1):50-4. PubMed ID: 12576925
[TBL] [Abstract][Full Text] [Related]
3. The role of taxanes in the adjuvant treatment of early stage breast cancer.
Piccart M
Breast Cancer Res Treat; 2003; 79 Suppl 1():S25-34. PubMed ID: 12868803
[TBL] [Abstract][Full Text] [Related]
4. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
6. Risks and benefits of taxanes in breast and ovarian cancer.
Michaud LB; Valero V; Hortobagyi G
Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
[TBL] [Abstract][Full Text] [Related]
7. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models.
Naito M; Matsuba Y; Sato S; Hirata H; Tsuruo T
Clin Cancer Res; 2002 Feb; 8(2):582-8. PubMed ID: 11839680
[TBL] [Abstract][Full Text] [Related]
8. Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Radaideh SM; Sledge GW
Breast Cancer Res Treat; 2008 Sep; 111(2):203-8. PubMed ID: 17990102
[TBL] [Abstract][Full Text] [Related]
9. Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure.
Makarovskiy AN; Siryaporn E; Hixson DC; Akerley W
Cell Mol Life Sci; 2002 Jul; 59(7):1198-211. PubMed ID: 12222966
[TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
Sharma A; Straubinger RM; Ojima I; Bernacki RJ
J Pharm Sci; 1995 Dec; 84(12):1400-4. PubMed ID: 8748320
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines.
Riccardi A; Servidei T; Tornesello A; Puggioni P; Mastrangelo S; Rumi C; Riccardi R
Eur J Cancer; 1995; 31A(4):494-9. PubMed ID: 7576952
[TBL] [Abstract][Full Text] [Related]
12. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
Seidman AD; Hochhauser D; Gollub M; Edelman B; Yao TJ; Hudis CA; Francis P; Fennelly D; Gilewski TA; Moynahan ME; Currie V; Baselga J; Tong W; O'Donaghue M; Salvaggio R; Auguste L; Spriggs D; Norton L
J Clin Oncol; 1996 Jun; 14(6):1877-84. PubMed ID: 8656256
[TBL] [Abstract][Full Text] [Related]
13. Taxane-based therapy for breast cancer: combination or sequential therapy?
Sparano JA; Rajdev L
Cancer Invest; 2000; 18(5):498-500. PubMed ID: 10834036
[No Abstract] [Full Text] [Related]
14. Docetaxel is a potent cytotoxic drug in the treatment of advanced breast cancer.
Van Vaerenbergh W; Paridaens R; Thomas J; Wildiers J; Van Oosterom A
Acta Clin Belg; 1998 Aug; 53(4):264-9. PubMed ID: 9795447
[TBL] [Abstract][Full Text] [Related]
15. Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells.
Distefano M; Scambia G; Ferlini C; Gaggini C; De Vincenzo R; Riva A; Bombardelli E; Ojima I; Fattorossi A; Panici PB; Mancuso S
Int J Cancer; 1997 Sep; 72(5):844-50. PubMed ID: 9311603
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the linearity of docetaxel pharmacokinetics.
McLeod HL; Kearns CM; Kuhn JG; Bruno R
Cancer Chemother Pharmacol; 1998; 42(2):155-9. PubMed ID: 9654116
[TBL] [Abstract][Full Text] [Related]
17. Taxanes: an overview of the pharmacokinetics and pharmacodynamics.
Vaishampayan U; Parchment RE; Jasti BR; Hussain M
Urology; 1999 Dec; 54(6A Suppl):22-9. PubMed ID: 10606281
[TBL] [Abstract][Full Text] [Related]
18. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.
Chan DC; Earle KA; Zhao TL; Helfrich B; Zeng C; Baron A; Whitehead CM; Piazza G; Pamukcu R; Thompson WJ; Alila H; Nelson P; Bunn PA
Clin Cancer Res; 2002 Mar; 8(3):904-12. PubMed ID: 11895925
[TBL] [Abstract][Full Text] [Related]
19. The taxoids. Comparative clinical pharmacology and therapeutic potential.
Eisenhauer EA; Vermorken JB
Drugs; 1998 Jan; 55(1):5-30. PubMed ID: 9463787
[TBL] [Abstract][Full Text] [Related]
20. Oral delivery of taxanes.
Malingré MM; Beijnen JH; Schellens JH
Invest New Drugs; 2001 May; 19(2):155-62. PubMed ID: 11392449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
